KSCP
APFCP
SIUCP-ETS
Search
- Page Path
- HOME > Search
- Transanal Endoscopic Microsurgery for the Treatment of Well-Differentiated Rectal Neuroendocrine Tumors
- Hyoung Ran Kim, Woo Yong Lee, Kyung Uk Jung, Hyuk Jun Chung, Chul Joong Kim, Hae-Ran Yun, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun
- J Korean Soc Coloproctol. 2012;28(4):201-204. Published online August 31, 2012
- DOI: https://doi.org/10.3393/jksc.2012.28.4.201
- 3,996 View
- 30 Download
- 8 Citations
-
Abstract
PDF Purpose Recently, an increase in well-differentiated rectal neuroendocrine tumors (WRNETs) has been noted. We aimed to evaluate transanal endoscopic microsurgery (TEM) for the treatment of WRNETs.
Methods Between December 1995 and August 2009, 109 patients with WRNETs underwent TEM. TEM was performed for patients with tumors sizes of up to 20 mm and without a lymphadenopathy. These patients had been referred from other clinics after having been diagnosed with WRNETs by using a colonoscopic biopsy; they had undergone a failed endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) and exhibited an involved resection margin and remaining tumor after ESD or EMR, regardless of the distance from the anal verge. This study included 38 patients that had more than three years of follow-up.
Results The mean age of the patients was 51.3 ± 11.9 years, the mean tumor size was 8.0 ± 3.9 mm, and no morbidity occurred. Thirty-five patients were asymptomatic. TEM was performed after a colonoscopic resection in 13 cases because of a positive resection margin, a residual tumor or a non-lifting lesion. Complete resections were performed in 37 patients; one patient with a positive margin was considered surgically complete. In one patient, liver metastasis and a recurrent mesorectal node occurred after five and 10 years, respectively.
Conclusion TEM might provide an accessible and effective treatment either as an initial or as an adjunct after a colonoscopic resection for a WRNET.
-
Citations
Citations to this article as recorded by
- Oncological outcomes according to the treatment modality based on the size of rectal neuroendocrine tumors: a single-center retrospective study
Jimin Son, In Ja Park, Dong-Hoon Yang, Jisup Kim, Kyoung-Jo Kim, Jeong-Sik Byeon, Seung Mo Hong, Young Il Kim, Jong Beom Kim, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
Surgical Endoscopy.2022; 36(4): 2445. CrossRef - Long-term outcomes of transanal endoscopic microsurgery for the treatment of rectal neuroendocrine tumors
Wei-Kun Shi, Rui Hou, Yun-Hao Li, Xiao-Yuan Qiu, Yu-Xin Liu, Bin Wu, Yi Xiao, Jiao-Lin Zhou, Guo-Le Lin
BMC Surgery.2022;[Epub] CrossRef - Non-conventional applications for transanal endoscopic microsurgery. A single center experience and a systematic review of literature
Rosita DE VINCENTI, Fabio CIANCHI, Francesco CORATTI
Minerva Surgery.2022;[Epub] CrossRef - Transanalis műtéti útmutató – második kiadás
Kálmán Almási, Szabolcs Ábrahám, József Baracs, Attila Bursics, Zoltán Jánó, Tamás Sztipits, Áron Szűts, Dezső Tóth, Attila Zaránd, Balázs Bánky
Orvosi Hetilap.2022; 163(Supplement): 3. CrossRef - Endoscopic submucosal dissection versus transanal local excision for rectal carcinoid: a comparative study
Fei-hu Yan, Zheng Lou, Shi-jie Hu, Xiao-dong Xu, Hao Wang, Han-tao Wang, Rong-gui Meng, Chuan-gang Fu, Wei Zhang, Jian He, En-da Yu
World Journal of Surgical Oncology.2016;[Epub] CrossRef - Efficacy and Safety of Endoscopic Resection Therapies for Rectal Carcinoid Tumors: A Meta-Analysis
Lei He, Tao Deng, Hesheng Luo
Yonsei Medical Journal.2015; 56(1): 72. CrossRef - Full-thickness excision using transanal endoscopic microsurgery for treatment of rectal neuroendocrine tumors
Wei-Jie Chen
World Journal of Gastroenterology.2015; 21(30): 9142. CrossRef - Current Issues Involving the Treatment of Small Rectal Carcinoid Tumors
Dae Kyung Sohn
Journal of the Korean Society of Coloproctology.2012; 28(4): 176. CrossRef
- Oncological outcomes according to the treatment modality based on the size of rectal neuroendocrine tumors: a single-center retrospective study
- Treatment Outcomes of Anorectal Melanoma
- Byung Min Choi, Hyoung Ran Kim, Hae-Ran Yun, Seung Ho Choi, Yong Beom Cho, Hee Cheol Kim, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun
- J Korean Soc Coloproctol. 2011;27(1):27-30. Published online February 28, 2011
- DOI: https://doi.org/10.3393/jksc.2011.27.1.27
- 3,251 View
- 40 Download
- 18 Citations
-
Abstract
PDF
Purpose An anorectal melanoma (AM) is a very rare tumor. However, sufficient data supporting effective surgical options for the disease do not exist. This retrospective review aimed to analyze treatment outcomes for an AM.
Methods From June 1999 to December 2008, we retrospectively reviewed a prospectively collected consecutive series of 19 patients who had undergone a surgical resection for an AM at a single institute. Surgical method and clinicopathological factors were analyzed.
Results The median age was 61.4 years (range, 46 to79 years). Main symptoms were an anal mass, hematochezia, perianal pain, tenesmus, fecal incontinence, and bowel habit change. The average duration of symptoms before diagnosis was 7.8 months (range, 1 to 36 months). S-100 and HMB-45 were positive in all patients, even in non-melanin pigmentation. There were 12 abdominoperineal resections (APRs) and 7 wide local excisions (WEs). The APR showed longer overall survival when compared with the WE (64.1 months vs. 10.9 months, P < 0.001). No patients who underwent a WE survived more than 13 months.
Conclusion A high index of suspicion is necessary to establish the diagnosis for an AM in patients with anal symptoms, and S-100 and HMB-45 can be useful markers for an AM. Even with the small number of cases and the short follow-up, our data suggest that an APR for an AM may provide longer survival than a WE.
-
Citations
Citations to this article as recorded by- Optimal surgical management strategy for treatment of primary anorectal malignant melanoma—a systematic review and meta-analysis
Hugo C. Temperley, Niall J. O’Sullivan, Alan Keyes, Dara O. Kavanagh, John O. Larkin, Brian J. Mehigan, Paul H. McCormick, Michael E. Kelly
Langenbeck's Archives of Surgery.2022; 407(8): 3193. CrossRef - Trends in the management of anorectal melanoma: A multi-institutional retrospective study and review of the world literature
Josh Bleicher, Jessica N Cohan, Lyen C Huang, William Peche, T Bartley Pickron, Courtney L Scaife, Tawnya L Bowles, John R Hyngstrom, Elliot A Asare
World Journal of Gastroenterology.2021; 27(3): 267. CrossRef - Survival following surgical treatment for anorectal melanoma seems similar for local excision and extensive resection regardless of nodal involvement
E. Jutten, S. Kruijff, A.B. Francken, H.L. van Westreenen, K.P. Wevers
Surgical Oncology.2021; 37: 101558. CrossRef - Response to Kahlke et al
Audrius Dulskas
Colorectal Disease.2021; 23(11): 3029. CrossRef - Three Cases of Anorectal Malignant Melanoma Treated with Laparoscopic Abdominoperineal Resection
Shin Yoshida, Nobuaki Suzuki, Shinobu Tomochika, Yoshitaro Shindo, Yukio Tokumitsu, Michihisa Iida, Shigeru Takeda, Tatsuya Ioka, Shoichi Hazama, Tsuzuri Shirahama, Hiroo Kawano, Eiji Ikeda, Hiroaki Nagano
The Japanese Journal of Gastroenterological Surgery.2021; 54(9): 644. CrossRef - Spectrum of presentation in primary anorectal malignant melanoma and its management
Barun Kumar Singh, Samrat Ray, Shashi Dhawan, Samiran Nundy
BMJ Case Reports.2021; 14(10): e245449. CrossRef - Surgical treatment of anorectal melanoma: a systematic review and meta-analysis
Esther Jutten, Schelto Kruijff, Anne Brecht Francken, Martijn F Lutke Holzik, Barbara L van Leeuwen, Henderik L van Westreenen, Kevin P Wevers
BJS Open.2021;[Epub] CrossRef - Long-term Oncologic Outcome and Its Relevant Factors in Anal Cancer in Korea: A Nationwide Data Analysis
Hyuk Hur, Kyu-Won Jung, Byung-Woo Kim, Chang-Mo Oh, Young-Joo Won, Jae Hwan Oh, Nam Kyu Kim
Annals of Coloproctology.2020; 36(1): 35. CrossRef - Primary anorectal malignant melanoma with laparoscopic abdominoperineal resection: a case study and review of the relevant literature
Kentaro Nonaka, Kensuke Kudou, Shun Sasaki, Tomoko Jogo, Kosuke Hirose, Yuta Kasagi, Qingjiang Hu, Yasuo Tsuda, Yuichi Hisamatsu, Koji Ando, Yuichiro Nakashima, Hiroshi Saeki, Eiji Oki, Mitsuo Kamori, Masaki Mori
International Cancer Conference Journal.2020; 9(3): 116. CrossRef - Less is more: A systematic review and meta-analysis of the outcomes of radical versus conservative primary resection in anorectal melanoma
Henry G. Smith, Jessica Glen, Nancy Turnbull, Howard Peach, Ruth Board, Miranda Payne, Martin Gore, Karen Nugent, Myles J.F. Smith
European Journal of Cancer.2020; 135: 113. CrossRef - Anorectal Malignant Melanoma: Retrospective Analysis of Six Patients and Review of the Literature
Ibrahim Atak
Prague Medical Report.2018; 119(2-3): 97. CrossRef - Extensive surgery and lymphadenectomy do not improve survival in primary melanoma of the anorectum: results from analysis of a large database (SEER)
A. Ciarrocchi, R. Pietroletti, F. Carlei, G. Amicucci
Colorectal Disease.2017; 19(2): 158. CrossRef - Das anorektale maligne Melanom
T. R. Glowka, M. D. Keyver-Paik, T. Thiesler, J. Landsberg, J. C. Kalff, D. Pantelis
Der Chirurg.2016; 87(9): 768. CrossRef - Abdominoperineal Resection Provides Better Local Control But Equivalent Overall Survival to Local Excision of Anorectal Malignant Melanoma
Akihisa Matsuda, Masao Miyashita, Satoshi Matsumoto, Goro Takahashi, Takeshi Matsutani, Takeshi Yamada, Taro Kishi, Eiji Uchida
Annals of Surgery.2015; 261(4): 670. CrossRef - Anorectal malignant melanoma: retrospective analysis of management and outcome in a single Portuguese Institution
Isália Miguel, João Freire, Maria José Passos, António Moreira
Medical Oncology.2015;[Epub] CrossRef - Characteristics and Survival of Korean Anal Cancer From the Korea Central Cancer Registry Data
Hyoung-Chul Park, Kyu-Won Jung, Byung-Woo Kim, Aesun Shin, Young-Joo Won, Jae Hwan Oh, Seung-Yong Jeong, Chang Sik Yu, Bong Hwa Lee
Annals of Coloproctology.2013; 29(5): 182. CrossRef - Incidence and Survival Patterns of Rare Anal Canal Neoplasms Using the Surveillance Epidemiology and End Results Registry
Cristina Metildi, Elisabeth C. McLemore, Thuy Tran, David Chang, Bard Cosman, Sonia L. Ramamoorthy, Sidney L. Saltzstein, Georgia Robins Sadler
The American Surgeon.2013; 79(10): 1068. CrossRef - Rectal melanoma
N. Patelis, P. Marselos, G. Sotiropoulou, S. Georgiou, A. Kominea
Hellenic Journal of Surgery.2012; 84(3): 198. CrossRef
- Optimal surgical management strategy for treatment of primary anorectal malignant melanoma—a systematic review and meta-analysis
- Oncologic Outcome after Cessation or Dose Reduction of Capecitabine in Patients with Colon Cancer
- Jung-A Yun, Hee Cheol Kim, Hyun-Sook Son, Hyoung Ran Kim, Hae Ran Yun, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun
- J Korean Soc Coloproctol. 2010;26(4):287-292. Published online August 31, 2010
- DOI: https://doi.org/10.3393/jksc.2010.26.4.287
- 3,334 View
- 38 Download
- 5 Citations
-
Abstract
PDF
Purpose Oral capecitabine has been used as adjuvant therapy for colorectal cancer patients since the 1990s. Patient-initiated cessation or reduced use of capecitabine occurs widely for various reasons, yet the consequences of these actions are unclear. The present study sought to clarify treatment outcomes in such patients.
Methods The study included 173 patients who had been diagnosed with stage II or III colon cancer according to the pathologic report after radical surgery at Samsung Medical Center from May 2005 to June 2007 and who had received capecitabine as adjuvant therapy. The patients were divided into groups according to whether the dose was reduced (I, dose maintenance; II, dose reduction) or stopped (A, cycle completion; B, cycle cessation). Recurrence and disease-free survival rates between the two groups each were analyzed.
Results Of the 173 patients, 128 (74.6%) experienced complications, most frequently hand-foot syndrome (n = 114). Reduction (n = 35) or cessation (n = 18) of medication was most commonly due to complications. Concerning reduced dosage, both groups displayed no statistically significant differences in recurrence rate and 3-year disease-free survival rate. Concerning discontinued medication use, the cycle completion group showed an improved recurrence rate (P = 0.048) and 3-year disease-free survival rate (P = 0.028).
Conclusion The results demonstrate that maintaining compliance with capecitabine as an adjuvant treatment for colon cancer to preventing complications positively affects patient prognosis.
-
Citations
Citations to this article as recorded by- The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients
Doreen Z. Mhandire, Andrew K. L. Goey
Molecular Diagnosis & Therapy.2022; 26(2): 137. CrossRef - Global Cancer Burden and Natural Disasters: A Focus on Asia’s Vulnerability, Resilience Building, and Impact on Cancer Care
Roselle De Guzman, Monica Malik
Journal of Global Oncology.2019; (5): 1. CrossRef - Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer
Devon J. Boyne, Colleen A. Cuthbert, Dylan E. O’Sullivan, Tolulope T. Sajobi, Robert J. Hilsden, Christine M. Friedenreich, Winson Y. Cheung, Darren R. Brenner
JAMA Network Open.2019; 2(5): e194154. CrossRef - 5-fluorouracil Toxicity Mechanism Determination in Human Keratinocytes: in vitro Study on HaCaT Cell Line
Jan Hartinger, Pavel Veselý, Martin Šíma, Irena Netíková, Eva Matoušková, Luboš Petruželka
Prague Medical Report.2017; 118(4): 128. CrossRef - An exploratory study to identify risk factors for the development of capecitabine‐induced Palmar Plantar Erythrodysesthesia (PPE)
Annie Law, Sue Dyson, Denis Anthony
Journal of Advanced Nursing.2015; 71(8): 1825. CrossRef
- The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients
First
Prev
TOP
